Navigation Links
Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta
Date:8/5/2008

- $25 Million Interferon-Beta-CTP Development Program Has Been Approved For First Year Funding Through a Special Grant From the Israeli Office of the

Chief Scientist -

NES-ZIONA, Israel, Aug. 5 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG) today reported that its Israeli-based R&D subsidiary has received approval for a special grant from the Israeli Office of the Chief Scientist ("OCS") in support of the company's development program for interferon-beta-CTP (IFN-Beta-CTP), its longer-acting version of interferon beta. Interferon-beta is an injectable treatment for multiple sclerosis (MS).

In preclinical experiments, IFN-Beta-CTP has shown durability of therapeutic effect, or half-life, almost seven times greater (6.7-fold longer) than the durability of effect of commercial interferon beta. The data demonstrated the potential to significantly reduce the number of required injections of interferon beta, which would greatly increase patient convenience.

The OCS has approved a special grant to support Modigene's IFN-Beta-CTP program for 2008-2009. The grant will provide cash reimbursements of 40% of expenses paid for IFN-Beta-CTP product development during this period. Modigene's full IFN-Beta-CTP development program, as submitted to the OCS, is based on an estimated development budget of $25 million for calendar years 2008-2011. IFN-Beta-CTP is currently in preclinical development, with clinical trials expected to begin in 2009.

Interferon beta is a drug used to reduce the frequency and severity of relapses afflicting people suffering from MS, an autoimmune neurological disorder affecting the insulating myelin layers of the brain and spinal cord. If unchecked, over time the immune system attack on myelin leads to poor coordination, severe disabilities and premature death. Annual sales of interferon beta were estimated to be $4.3 billion in 2007.

"This generous new grant from the
'/>"/>

SOURCE Modigene Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Modigene Platform Validated in Independent Phase III Trial of CTP Technology
2. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
3. GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
4. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
5. Discovering How Video Games Can Motivate Healthy Behaviors: More than $2 Million Awarded to 12 Research Teams Across U.S.
6. TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
7. New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity
8. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
9. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
10. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
11. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... 4 AstraZeneca (NYSE: AZN ) today ... has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release ... with Major Depressive Disorder (MDD). SEROQUEL XR is the ... to treat both major depressive disorder as adjunctive therapy ...
(Date:12/3/2009)... , a leading primary research firm, today announced the launch ... that monitors and projects trends and market share in the ... captures actual patient usage for 87 different Sleep Apnea mask ... providers going back to January 2006. In the most ...
(Date:12/3/2009)... and STATE COLLEGE, Pa., Dec. 3 Ambry ... an agreement to provide extended bioinformatics genomics services ... performed at Ambry. ,, (Logo: ... CSO said, "Our team at Ambry has been ...
Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Critical Signal Technologies Acquires Link to Life to Grow Depth and Expertise in TeleHealth Personal Emergency Response and Medical Monitoring Syste 57351 1Critical Signal Technologies Acquires Link to Life to Grow Depth and Expertise in TeleHealth Personal Emergency Response and Medical Monitoring Syste 57351 2Critical Signal Technologies Acquires Link to Life to Grow Depth and Expertise in TeleHealth Personal Emergency Response and Medical Monitoring Syste 57351 3Sinovac to Present at 2009 UBS Global Life Sciences Conference 14092 1Sinovac to Present at 2009 UBS Global Life Sciences Conference 14092 2How to reach proficiency in laparoscopic splenectomy 3F 57347 1
... plans initiation of clinical studies; Data to be ... 21 Drug discovery and development company Esperance ... preclinical program that support the initiation of ... candidate from the Company,s Cationic Lytic Peptide (CLYP(TM)) ...
... NanoVibronix, a medical device,company specializing in applications ... novel device has received CE approval in ... is the first hands-free,patch-based device that uses ... The innovative PainShield consists of a disposable ...
Other Medicine Technology:First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept 2First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept 3NanoVibronix Receives Wound Healing Indications in Europe for its PainShield(TM) Device 2
(Date:12/7/2009)... Consolidated Access to Interdisciplinary Evidence-based Content throughout the Clinical ... ... (PRWEB) December 7, 2009 -- Institutions currently using point-of-care ... Zynx Health will benefit from a new ... evidence-based resources, resulting in quicker retrieval of relevant and ...
(Date:12/7/2009)... free tax calculator. Answer simple questions about income and watch the tax ... ... return by using the free tax calculator. , , , , ,The calculator ... or worrying about how much the return will be or how much tax ... Find out right now with a few clicks of the mouse. , ...
(Date:12/7/2009)... Dec. 7 Cell Therapeutics, Inc. ("CTI") ... Pettengell, M.D. of St. George,s Hospital, University of ... Society of Hematology ("ASH") Annual Meeting updated results ... clinical trial of pixantrone (the "PIX 301 EXTEND ... ("NHL") patients who have failed 2 or ...
(Date:12/7/2009)... be able to reverse some of the damage to ... down their cigarettes, according to research out of the ... research is published in the December 15 issue of ... and Critical Care Medicine . , "We found that ... of the epithelium, or lining, of the airways in ...
(Date:12/6/2009)... Antonio Bay ,, SILVER SPRING, Md., Dec. 6 ... advising consumers to avoid eating oysters harvested from the ... to reports of norovirus-associated illnesses in some people who ... located on the Gulf of Texas. ,, (Logo: ... with the Centers for Disease Control and Prevention (CDC) ...
Breaking Medicine News(10 mins):Health News:EBSCO Publishing and Zynx Health Expand Partnership for Integrated Access to Evidence-Based Content 2Health News:EBSCO Publishing and Zynx Health Expand Partnership for Integrated Access to Evidence-Based Content 3Health News:2009 Free Tax Return Calculator 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Quitting smoking can reverse asthma-inducing changes in lungs 2Health News:FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters 2
... for fat people and inventors. ,Scientists have always sought ... are no exception. //Currently, two thirds of the population can be ... put a morbidly obese figure of 2.2 million pounds ... ,Bloom’s quest is to create a chewing gum or nasal ...
... Eating too much of unhealthy trans fats present in many ... ,Scientists at the Harvard School of Public Health found ... trans fats than fertile women, reported the online edition of ... fat that is formed when vegetable oils are hardened into ...
... A new study reveals the full extent of psychological problems ... About half of those surveyed showed signs of clinical depression, ... findings may not be surprising, specialists are calling them a ... resources to mental healing. ,'In addition to ...
... called nestin to a particularly deadly form of breast ... earlier detection and better treatment.// ,In the January ... School demonstrate that nestin could represent a selective biological ... cancer with similarities to mammary stem cells, the regenerative ...
... the pubic bone as a source of bone for grafting ... crest, or 'hip bone,' according to a report in the ... further study, the pubic bone could become the new standard ... write Dr. John W. Polley and colleagues of Rush University ...
... very word ‘bird flu’ sets them in jitters, take a ... presence of avian influenza or bird flu, //in a Japanese ... birds have died from the disease at a farm situated ... Fisheries Ministry have confirmed the cause of the chicken death ...
Other Medicine News:Health News:Chew That Fat Away 2Health News:Burn Patients Need More Help Coping With Depression 2Health News:Selective Marker Found to Indicate Aggressive Form of Breast Cancer 2Health News:Selective Marker Found to Indicate Aggressive Form of Breast Cancer 3Health News:New Technique Uses Pubic Bone for Grafting 2
... USIOL lenses are manufactured using ... processes. Perspex CQ UV PMMA ... multi-piece and single piece lenses. ... in both nonphaco and phaco ...
Optical implants for the replacement of the human crystalline lens in the visual correction of aphakia....
1% Sodium Hyaluronate, 10mg/mL, sterile opthalmic injection...
... with optimum molecular weight and viscosity, so ... coats and protects the delicate structures of ... balance of cohesion, adhesion, and pseudoplasticity to ... phaco surgeon expects from an ophthalmic viscoelastic ...
Medicine Products: